menu
    • menu
    [{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"K102","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal","highestDevelopmentStatusID":"1","companyTruncated":"Kashiv Specialty Pharmaceuticals \/ Amneal"},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Filgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Phase III","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Specialty Pharmaceuticals \/ Amneal"}]

    Find Clinical Drug Pipeline Developments & Deals by Kashiv Specialty Pharmaceuticals

    Menu

    Kashiv Specialty Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kashiv Specialty Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kashiv Specialty Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals

                            Details : Amneal Pharmaceuticals has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and no...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 05, 2021

                            Lead Product(s) : Filgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kashiv Specialty Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kashiv Specialty Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : K102

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Amneal Pharmaceuticals

                            Deal Size : $108.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Amneal to Acquire Substantially all of Kashiv Specialty Pharmaceuticals

                            Details : The acquisition enhances Amneal's R&D expertise with the addition of the Kashiv Specialty team and its impressive track record in developing complex generic products (e.g. Yuvafem and EluRyng) and innovative drug delivery technologies.

                            Brand Name : K102

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 12, 2021

                            Lead Product(s) : K102

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Amneal Pharmaceuticals

                            Deal Size : $108.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth